Joshua Jennings
Stock Analyst at TD Cowen
(3.31)
# 995
Out of 5,163 analysts
81
Total ratings
46.75%
Success rate
3.69%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BFLY Butterfly Network | Maintains: Buy | $4.5 → $6 | $3.80 | +57.89% | 1 | Feb 27, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $50 → $34 | $27.13 | +25.32% | 5 | Feb 26, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $115 → $100 | $69.13 | +44.66% | 8 | Feb 5, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $222 → $250 | $241.52 | +3.51% | 2 | Jan 22, 2026 | |
| EW Edwards Lifesciences | Upgrades: Buy | $90 → $97 | $81.81 | +18.57% | 2 | Jan 9, 2026 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $4.20 | +257.14% | 1 | Dec 10, 2025 | |
| CBLL CeriBell | Maintains: Buy | $36 → $20 | $18.49 | +8.17% | 3 | Nov 5, 2025 | |
| SENS Senseonics Holdings | Maintains: Buy | $25 → $15 | $5.64 | +165.96% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $64.24 | +30.76% | 2 | Oct 31, 2025 | |
| HUMA Humacyte | Maintains: Buy | $5 → $3.5 | $1.16 | +201.72% | 3 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.19 | +142.33% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $324 | $219.84 | +47.38% | 1 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $120 | $123.48 | -2.82% | 9 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $93.20 | +27.68% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $32.54 | +84.42% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $76.74 | +4.25% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $3.26 | +1,282.49% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $17.40 | +129.89% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $336.77 | +18.78% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $63.35 | -5.29% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $21.59 | +57.48% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $5.51 | +226.68% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $16.58 | +50.78% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $108.03 | +20.34% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $1.89 | +164.55% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $87.14 | +34.27% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $12.28 | -2.28% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $159.36 | +72.57% | 1 | Feb 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $28 | $10.05 | +173.63% | 3 | Sep 5, 2018 |
Butterfly Network
Feb 27, 2026
Maintains: Buy
Price Target: $4.5 → $6
Current: $3.80
Upside: +57.89%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Buy
Price Target: $50 → $34
Current: $27.13
Upside: +25.32%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $115 → $100
Current: $69.13
Upside: +44.66%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $222 → $250
Current: $241.52
Upside: +3.51%
Edwards Lifesciences
Jan 9, 2026
Upgrades: Buy
Price Target: $90 → $97
Current: $81.81
Upside: +18.57%
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $4.20
Upside: +257.14%
CeriBell
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $18.49
Upside: +8.17%
Senseonics Holdings
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $5.64
Upside: +165.96%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $64.24
Upside: +30.76%
Humacyte
Aug 12, 2025
Maintains: Buy
Price Target: $5 → $3.5
Current: $1.16
Upside: +201.72%
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $6.19
Upside: +142.33%
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $219.84
Upside: +47.38%
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $123.48
Upside: -2.82%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $93.20
Upside: +27.68%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $32.54
Upside: +84.42%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $76.74
Upside: +4.25%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $3.26
Upside: +1,282.49%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $17.40
Upside: +129.89%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $336.77
Upside: +18.78%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $63.35
Upside: -5.29%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $21.59
Upside: +57.48%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $5.51
Upside: +226.68%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $16.58
Upside: +50.78%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $108.03
Upside: +20.34%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.89
Upside: +164.55%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $87.14
Upside: +34.27%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $12.28
Upside: -2.28%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $159.36
Upside: +72.57%
Sep 5, 2018
Downgrades: Market Perform
Price Target: $28 → $28
Current: $10.05
Upside: +173.63%